Syntaxin

About Syntaxin

In the world of biotech, you often see foundational science spin out from universities, and that’s exactly the playbook for Syntaxin. The company was co-founded by Dr. Keith Foster and Dr. John Chaddock, who leveraged deep expertise in botulinum toxins. Their focus wasn't on cosmetics, but on the therapeutic potential of these powerful molecules, engineering them to treat a range of debilitating diseases. Syntaxin’s core technology centered on creating recombinant botulinum toxins, essentially designing and building new versions with improved properties. This attracted significant attention, and by 2010, they had entered into a collaboration with the French pharmaceutical company Ipsen. This partnership was a classic “dance before the wedding.” Ipsen, a major player in the toxin space with its product Dysport, got an inside look at Syntaxin's innovative platform. A year later, the collaboration deepened into a strategic partnership, and by this point, Ipsen already owned about 10% of the company. The big event came in July 2013 when Ipsen decided to acquire Syntaxin outright. The deal was structured with an upfront payment of €28 million, with the potential for over €130 million more based on future milestones. For Ipsen, it was a strategic move to bolster its R&D pipeline and solidify its leadership in neurology. For Syntaxin, it was the culmination of years of focused research, transitioning from a private UK life sciences company to a key innovation engine within a global pharmaceutical firm, with its founders joining Ipsen to continue their work.